UNSPSC 51342905: Vidarabine anhydrous

This classification denotes a purine antagonist and antiviral agent with the molecular formula C10H13N5O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3XQD2MEW34, chemically known as vidarabine, anhydrous, but more generally known as vidarabine anhydrous, which bears US NIH Compound Identifier 21704. European Medicines Agency schedules vidarabine anhydrous or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00047MIG.

Most nations, for tariff purposes, schedule vidarabine anhydrous under HS 29349990. Vidarabine anhydrous bears US NLM identifiers UMLS ID C2700247 and NCI Concept Code C77393. SMILES: C1NC(C2C(N1)N(CN2)[C@H]3[C@H]([C@@H]([C@H](O3)CO)O)O)N.

UNSPSC 51342905 Vidarabine anhydrous, a Commodity code, does not show relevant recent activity under state and local procurement. The three recent opportunities tagged to this code involve naloxone procurement, therapeutic pharmacy initiative program design, medical and first aid supplies for fire departments, and generic multi-source pharmaceutical contracts — none of which are vidarabine or antivirals matching the code's nominal scope. The mismatch between the code name and the actual solicitations suggests either a data-quality issue in code assignment or minimal state and local demand for vidarabine as a standalone procurement item.

The opportunities present instead reflect broader pharmaceutical and health-supply procurement activity across Florida county government, Texas state health agencies, municipal fire departments, and multi-state cooperative purchasing consortia, but none target vidarabine specifically. Without recent solicitations aligned to the actual Commodity code definition, the code presents no clear commercial signal or opportunity pipeline for business development purposes at this time.